# Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis

> **NCT04502381** · PHASE2 · COMPLETED · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 30 (actual)

## Conditions studied

- Pulmonary Mucormycosis

## Interventions

- **DRUG:** Inhaled amp B deoxycholate+intravenous liposomal amp B
- **DRUG:** Intravenous liposomal amphotericin B alone

## Key facts

- **NCT ID:** NCT04502381
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502381, "Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04502381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*